A Phase 2 interventional study of Placebo and Romosozumab in Fracture Healing, sponsored by Amgen. Completed at 99 sites in 24 countries. Open to participants aged 55 Years to 95 Years. Per ClinicalTrials.gov, last updated 2022-09-21.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 133 studies in Hip Fractures with a site in United States — 22 open to participants now, 31 under way, none of them phase 3. Hip Fractures · United States.
Among the 133 studies in Hip Fractures with a site in United States, this one is the 16th largest by enrollment of the 105 interventional ones that give a count, is the only one that started in 2010, is one of 16 in phase 2, and was the 29th registered.
843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.
Browse Hip Fractures studies →22 of the 133 studies in Hip Fractures with a site in United States are open now. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 65+
SI-BONE, Inc. · Sites in United States
Ages 60+
University of Maryland, Baltimore · Sites in United States
Ages 60+
University of Southern California · Sites in United States, Canada, Norway and 2 more countries
Ages 60+
Yale University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.
This study: 55 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
133 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 10 · Phase 4 15
First in 1980; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 332 is above the median of 86 across 534 interventional studies indexed under Hip Fractures.
Median enrollment 64 across the 105 interventional studies, 160 across the 26 observational. Of the 84 that completed or were terminated, 36 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 133 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 2 studies filed under Hip Fractures — fewer than ten, so there is no comparison to draw.
16 of the studies in Hip Fractures with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06407427Yale UniversityEvaluating the Efficacy of a Mobile Application in Postoperative Rehabilitation | 2026-12 |
| NCT04809714University of Alabama at BirminghamThe Role of Blood Flow Restriction Therapy in Postoperative Elderly Patients With Hip Fracture | 2026-12-13 |
| NCT04113044AO Innovation Translation CenterGo Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS® | 2026-12-31 |
| NCT06024304Paul E. MatuszewskiInterTAN: Integrated Dual Screw Design Improve Biomechanics/Function Following Fixation Surgery | 2027-01-01 |
| NCT04937868University of California, Los AngelesDeveloping a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients | 2027-01-15 |
Add all 16 to your calendar (.ics) → With an account.
Among the 133 studies in Hip Fractures with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an international, multi-center study to determine the efficacy, safety, and tolerability of romosozumab (AMG 785) in adults with a fresh unilateral hip fracture, status post surgical fixation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
internal fixation of the fracture with devices approved by local regulatory agency, performed no later than 7 days after injury for intertrochanteric or undisplaced femoral neck fractures and no later than 2 days after injury for displaced femoral neck fractures
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo to romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
Drug: Placebo
Participants received 70 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
Drug: Romosozumab
Participants received 140 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
Drug: Romosozumab
Participants received 210 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
Drug: Romosozumab
Administered by subcutaneous (under the skin) injection
Administered by subcutaneous injection
Also known as: AMG 785, Evenity
Timed-Up-and-Go (TUG) Over Week 6 Through Week 20
Functional healing was measured by the timed-up-and-go test (TUG) over Weeks 6 through 20. During this assessment, the clinician timed the participant while they stood up from a seated position in a chair, walked three meters, turned around, walked three meters back to the chair, and returned to the seated position. A TUG value of ten seconds or less was considered normal for a healthy elderly person. Higher TUG values after hip fracture have been shown to be a predictor of future falls. Least squares mean (LSM) estimates were based on a repeated measures model fitted with the log-transformed TUG values at weeks 2, 6, 12, 16, 20, 24, 36, 52 as the dependent variable and adjusted for treatment, randomized strata, gender, country category, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction and back-transformed using the exponential transformation.
Time frame: Weeks 6, 12, 16, and 20
Timed-Up-and-Go (TUG) at Each Visit
During the timed-up-and-go test the clinician timed the participant while they stood up from a seated position in a chair, walked 3 meters, turned around, walked 3 meters back to the chair, and returned to a seated position. A TUG value of ≤ 10 seconds is considered normal for a healthy elderly person. LSMs were based on a repeated measures model adjusting for treatment, randomized strata, gender, country category, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction. Missing TUG values for participants still on study were imputed using the last observation carried forward (LOCF) when possible. If no observation could be carried forward, the maximum TUG value observed among all participants at a given visit was used. TUG values obtained after unplanned revision surgery were replaced by carrying forward the last available observed or imputed value prior to unplanned revision surgery.
Time frame: Weeks 2, 6, 12, 16, 20, 24, 36, and 52
Time to Radiographic Healing
Time to radiographic healing is the time interval from the surgery date for the eligible hip fracture to the date of radiographic healing, defined as effacement of the fracture lines by newly formed bone along the cortices and within the trabecular bone on anteroposterior and lateral (or oblique) radiographs. Radiographic fracture healing was determined by a panel of independent reviewers blinded to treatment. The cumulative incidence function (CIF) method was used to estimate the median time to radiographic healing and the confidence intervals. Unplanned revision surgery to promote healing was considered a competing risk in CIF estimate.
Time frame: 52 weeks
Radiographic Union Scale for Hip (RUSH) Score At Each Visit
The radiographic Union Scale for Hip (RUSH) is a semiquantitative scoring assessment to assess hip fracture healing after surgical repair. The RUSH has 4 key domains based on radiographic parameters used by orthopedic surgeons and radiologists in routine clinical practice including cortical bridging (4 to 12 points), cortical fracture line disappearance (4 to 12 points), trabecular consolidation (1 to 3 points), and trabecular index disappearance of fracture line (1 to 3 points). The score has a minimum of 10 points (definitely not healed) and a maximum of 30 points (definitely healed).
Time frame: Weeks 2, 6, 12, 16, 20, 24, 36, and 52
Harris Hip Score At Each Visit
The Harris Hip Score is a clinician-based outcome that assesses pain, function, deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication. The function domain consists of daily activities and gait. Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction. The score ranges form 0-100 (best possible outcome) covering pain (0-44 points), function (0-47 points), absence of deformity (4 points), and range of motion (5 points). LSMs were based on a repeated measures model fitted with the Harris hip score values at weeks 2, 6, 12, 16, 20, 24, 36, and 52 as the dependent variable and adjusted for treatment, randomized strata, gender, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction.
Time frame: Weeks 2, 6, 12, 16, 20, 24, 36, and 52
Hip Pain Score at Each Visit
Hip pain was assessed using a visual analog scale (VAS). Participants were asked to rate their pain as a result of the hip fracture on a 100 mm vertical scale with 0 indicating no pain at all and 100 indicating the worst pain they could imagine. LSMs were based on a repeated measures model fitted with hip pain score values at weeks 2, 6, 12, 16, 20, 24, 36, and 52 as the dependent variable and adjusted for treatment, randomized strata, gender, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction.
Time frame: Weeks 2, 6, 12, 16, 20, 24, 36, and 52
This study was conducted at 63 centers in 22 countries in Eastern Europe, Western Europe, India, North America, Latin America, Australia, New Zealand and Hong Kong.
| Milestone | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Started | 89 | 60 | 93 | 90 |
| Received study drug | 87 | 60 | 89 | 89 |
| Completed 24 weeks of study | 73 | 50 | 72 | 68 |
| Completed | 62 | 44 | 62 | 61 |
| Not completed | 27 | 16 | 31 | 29 |
| Withdrew: Ineligibility determined | 0 | 0 | 1 | 1 |
| Withdrew: Noncompliance | 3 | 4 | 5 | 2 |
| Withdrew: Adverse event | 2 | 1 | 2 | 2 |
| Withdrew: Withdrawal by subject | 15 | 7 | 17 | 14 |
| Withdrew: Administrative decision | 1 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 4 | 1 | 4 | 3 |
| Withdrew: Death | 2 | 2 | 2 | 6 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
Functional healing was measured by the timed-up-and-go test (TUG) over Weeks 6 through 20. During this assessment, the clinician timed the participant while they stood up from a seated position in a chair, walked three meters, turned around, walked three meters back to the chair, and returned to the seated position. A TUG value of ten seconds or less was considered normal for a healthy elderly person. Higher TUG values after hip fracture have been shown to be a predictor of future falls. Least squares mean (LSM) estimates were based on a repeated measures model fitted with the log-transformed TUG values at weeks 2, 6, 12, 16, 20, 24, 36, 52 as the dependent variable and adjusted for treatment, randomized strata, gender, country category, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction and back-transformed using the exponential transformation.
| seconds | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Week 6 | 54.1 (44.4 to 66.0) | 41.0 (32.4 to 51.9) | 47.2 (38.9 to 57.4) | 53.3 (43.8 to 64.8) |
| Week 12 | 29.8 (25.3 to 35.2) | 27.6 (22.7 to 33.5) | 30.0 (25.6 to 35.2) | 36.1 (30.7 to 42.5) |
| Week 16 | 26.2 (22.2 to 30.8) | 23.3 (19.2 to 28.3) | 26.9 (23.0 to 31.6) | 31.8 (27.1 to 37.4) |
| Week 20 | 23.8 (20.3 to 28.0) | 21.9 (18.1 to 26.6) | 22.9 (19.5 to 26.8) | 29.1 (24.8 to 34.2) |
During the timed-up-and-go test the clinician timed the participant while they stood up from a seated position in a chair, walked 3 meters, turned around, walked 3 meters back to the chair, and returned to a seated position. A TUG value of ≤ 10 seconds is considered normal for a healthy elderly person. LSMs were based on a repeated measures model adjusting for treatment, randomized strata, gender, country category, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction. Missing TUG values for participants still on study were imputed using the last observation carried forward (LOCF) when possible. If no observation could be carried forward, the maximum TUG value observed among all participants at a given visit was used. TUG values obtained after unplanned revision surgery were replaced by carrying forward the last available observed or imputed value prior to unplanned revision surgery.
| seconds | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Week 2 | 132.3 (111.0 to 153.6) | 119.3 (94.2 to 144.4) | 121.7 (101.0 to 142.5) | 129.8 (108.9 to 150.7) |
| Week 6 | 92.4 (74.9 to 109.9) | 69.5 (48.6 to 90.4) | 80.3 (63.1 to 97.5) | 86.7 (69.3 to 104.0) |
| Week 12 | 47.4 (37.6 to 57.1) | 39.1 (27.4 to 50.7) | 44.6 (35.1 to 54.1) | 56.3 (46.6 to 65.9) |
| Week 16 | 43.1 (34.1 to 52.1) | 31.6 (20.9 to 42.4) | 39.7 (30.9 to 48.6) | 50.1 (41.2 to 59.1) |
| Week 20 | 36.4 (28.3 to 44.6) | 31.0 (21.2 to 40.7) | 35.1 (27.1 to 43.1) | 45.6 (37.5 to 53.8) |
| Week 24 | 33.3 (25.8 to 40.7) | 28.9 (20.1 to 37.8) | 31.7 (24.4 to 39.0) | 40.9 (33.5 to 48.4) |
| Week 36 | 32.4 (25.1 to 39.7) | 26.3 (17.5 to 35.0) | 29.8 (22.5 to 37.0) | 38.7 (31.3 to 46.0) |
| Week 52 | 28.7 (22.2 to 35.1) | 22.8 (15.2 to 30.5) | 28.8 (22.5 to 35.2) | 36.3 (29.8 to 42.7) |
Time to radiographic healing is the time interval from the surgery date for the eligible hip fracture to the date of radiographic healing, defined as effacement of the fracture lines by newly formed bone along the cortices and within the trabecular bone on anteroposterior and lateral (or oblique) radiographs. Radiographic fracture healing was determined by a panel of independent reviewers blinded to treatment. The cumulative incidence function (CIF) method was used to estimate the median time to radiographic healing and the confidence intervals. Unplanned revision surgery to promote healing was considered a competing risk in CIF estimate.
| weeks | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Time to Radiographic Healing | 16.4 (15.3 to 20.1) | 16.9 (12.9 to 20.3) | 16.6 (13.3 to 17.1) | 16.9 (13.3 to 20.9) |
The radiographic Union Scale for Hip (RUSH) is a semiquantitative scoring assessment to assess hip fracture healing after surgical repair. The RUSH has 4 key domains based on radiographic parameters used by orthopedic surgeons and radiologists in routine clinical practice including cortical bridging (4 to 12 points), cortical fracture line disappearance (4 to 12 points), trabecular consolidation (1 to 3 points), and trabecular index disappearance of fracture line (1 to 3 points). The score has a minimum of 10 points (definitely not healed) and a maximum of 30 points (definitely healed).
| units on a scale | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Week 2 | 12.1 ± 3.3 | 12.7 ± 3.5 | 12.1 ± 3.4 | 12.0 ± 3.1 |
| Week 6 | 18.1 ± 3.6 | 18.0 ± 4.2 | 18.4 ± 3.4 | 18.3 ± 4.0 |
| Week 12 | 23.3 ± 4.6 | 22.8 ± 4.8 | 22.9 ± 4.8 | 22.3 ± 5.3 |
| Week 16 | 25.6 ± 4.3 | 25.7 ± 4.5 | 25.5 ± 5.0 | 25.5 ± 4.7 |
| Week 20 | 26.8 ± 4.1 | 27.3 ± 4.1 | 27.4 ± 4.0 | 26.4 ± 4.6 |
| Week 24 | 27.8 ± 3.4 | 27.8 ± 3.9 | 28.3 ± 3.5 | 27.3 ± 3.9 |
| Week 36 | 28.7 ± 2.6 | 28.3 ± 3.6 | 29.1 ± 2.1 | 28.2 ± 3.5 |
| Week 52 | 29.4 ± 2.0 | 28.5 ± 3.8 | 29.6 ± 1.8 | 28.7 ± 3.3 |
The Harris Hip Score is a clinician-based outcome that assesses pain, function, deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication. The function domain consists of daily activities and gait. Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction. The score ranges form 0-100 (best possible outcome) covering pain (0-44 points), function (0-47 points), absence of deformity (4 points), and range of motion (5 points). LSMs were based on a repeated measures model fitted with the Harris hip score values at weeks 2, 6, 12, 16, 20, 24, 36, and 52 as the dependent variable and adjusted for treatment, randomized strata, gender, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction.
| units on a scale | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Week 2 | 46.6 (43.1 to 50.1) | 47.7 (43.6 to 51.9) | 47.3 (43.9 to 50.8) | 46.5 (43.1 to 50.0) |
| Week 6 | 58.6 (55.1 to 62.1) | 62.5 (58.3 to 66.7) | 61.6 (58.1 to 65.0) | 59.5 (55.9 to 63.0) |
| Week 12 | 71.2 (67.9 to 74.5) | 70.9 (67.0 to 74.9) | 71.7 (68.3 to 75.1) | 69.6 (66.2 to 72.9) |
| Week 16 | 74.1 (70.8 to 77.4) | 76.5 (72.6 to 80.5) | 76.1 (72.7 to 79.4) | 72.8 (69.4 to 76.2) |
| Week 20 | 76.2 (73.0 to 79.3) | 80.2 (76.4 to 83.9) | 80.5 (77.4 to 83.6) | 77.5 (74.3 to 80.7) |
| Week 24 | 79.0 (76.2 to 81.8) | 80.3 (76.8 to 83.7) | 83.0 (80.1 to 85.8) | 80.1 (77.2 to 83.0) |
| Week 36 | 80.3 (77.0 to 83.6) | 82.0 (78.1 to 85.8) | 86.8 (83.5 to 90.2) | 83.6 (80.2 to 86.9) |
| Week 52 | 84.3 (81.3 to 87.4) | 86.7 (83.0 to 90.3) | 89.0 (85.9 to 92.1) | 83.8 (80.7 to 86.9) |
Hip pain was assessed using a visual analog scale (VAS). Participants were asked to rate their pain as a result of the hip fracture on a 100 mm vertical scale with 0 indicating no pain at all and 100 indicating the worst pain they could imagine. LSMs were based on a repeated measures model fitted with hip pain score values at weeks 2, 6, 12, 16, 20, 24, 36, and 52 as the dependent variable and adjusted for treatment, randomized strata, gender, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction.
| units on a scale | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Week 2 | 34.3 (28.2 to 40.4) | 33.1 (25.9 to 40.3) | 40.3 (34.4 to 46.2) | 43.0 (37.1 to 48.9) |
| Week 6 | 26.3 (20.8 to 31.7) | 19.5 (13.1 to 26.0) | 25.1 (19.7 to 30.4) | 27.5 (22.1 to 32.9) |
| Week 12 | 19.4 (14.1 to 24.8) | 17.8 (11.5 to 24.1) | 17.5 (12.1 to 22.8) | 23.7 (18.3 to 29.0) |
| Week 16 | 18.1 (13.0 to 23.3) | 13.5 (7.4 to 19.6) | 16.8 (11.8 to 21.8) | 17.4 (12.2 to 22.5) |
| Week 20 | 15.8 (11.2 to 20.4) | 9.2 (3.8 to 14.7) | 14.0 (9.5 to 18.5) | 15.0 (10.5 to 19.6) |
| Week 24 | 13.8 (9.6 to 18.0) | 9.1 (4.0 to 14.2) | 12.7 (8.4 to 17.0) | 13.1 (8.8 to 17.3) |
| Week 36 | 14.3 (9.6 to 19.0) | 10.9 (5.4 to 16.4) | 11.6 (6.8 to 16.3) | 10.2 (5.5 to 14.9) |
| Week 52 | 13.4 (9.2 to 17.7) | 7.2 (2.1 to 12.3) | 9.3 (5.1 to 13.5) | 10.4 (6.2 to 14.6) |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 25/87 (28.7%) | 31/87 (35.6%) |
| Romosozumab 70 mg | — | 9/60 (15%) | 24/60 (40%) |
| Romosozumab 140 mg | — | 15/89 (16.9%) | 30/89 (33.7%) |
| Romosozumab 210 mg | — | 26/89 (29.2%) | 26/89 (29.2%) |
| Event | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| CellulitisInfections and infestations | 3/87 | 0/60 | 1/89 | 1/89 |
| Postoperative wound infectionInfections and infestations | 0/87 | 0/60 | 0/89 | 3/89 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/87 | 0/60 | 0/89 | 0/89 |
| Acute myocardial infarctionCardiac disorders | 1/87 | 0/60 | 1/89 | 2/89 |
| PneumoniaInfections and infestations | 1/87 | 0/60 | 1/89 | 2/89 |
| Hip fractureInjury, poisoning and procedural complications | 0/87 | 0/60 | 1/89 | 2/89 |
| Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 1/87 | 0/60 | 0/89 | 2/89 |
| Cardiac arrestCardiac disorders | 0/87 | 1/60 | 1/89 | 1/89 |
| Medical device complicationGeneral disorders | 0/87 | 1/60 | 0/89 | 1/89 |
| Medical device discomfortGeneral disorders | 0/87 | 1/60 | 0/89 | 0/89 |
| Event | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 11/87 | 6/60 | 9/89 | 6/89 |
| Back painMusculoskeletal and connective tissue disorders | 0/87 | 7/60 | 5/89 | 4/89 |
| DiarrhoeaGastrointestinal disorders | 8/87 | 2/60 | 2/89 | 4/89 |
| Urinary tract infectionInfections and infestations | 8/87 | 4/60 | 8/89 | 4/89 |
| NauseaGastrointestinal disorders | 7/87 | 4/60 | 7/89 | 2/89 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/87 | 3/60 | 6/89 | 5/89 |
| HypertensionVascular disorders | 3/87 | 4/60 | 5/89 | 4/89 |
| Procedural painInjury, poisoning and procedural complications | 5/87 | 1/60 | 5/89 | 2/89 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 5/87 | 0/60 | 0/89 | 2/89 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/87 | 3/60 | 5/89 | 2/89 |
| Age, Continuous(years) | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|---|---|
| Mean | 76.0 ± 8.6 | 76.6 ± 10.3 | 75.8 ± 10.1 | 76.7 ± 9.5 | 76.3 ± 9.5 |
| Age, Customized(Participants) | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|---|---|
| < 65 years | 10 | 8 | 17 | 11 | 46 |
| ≥ 65 years | 79 | 52 | 76 | 79 | 286 |
| Sex: Female, Male(Participants) | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|---|---|
| Female | 67 | 42 | 64 | 55 | 228 |
| Male | 22 | 18 | 29 | 35 | 104 |
| Race/Ethnicity, Customized(Participants) | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|---|---|
| White | 77 | 52 | 81 | 70 | 280 |
| Black or African American | 0 | 0 | 0 | 1 | 1 |
| Hispanic or Latino | 0 | 1 | 1 | 0 | 2 |
| Asian | 12 | 7 | 11 | 19 | 49 |
| Randomization Stratification(Participants) | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|---|---|
| Intertrochanteric, SHS and 55-75 years | 13 | 9 | 14 | 14 | 50 |
| Intertrochanteric, SHS and ≥ 76 years | 16 | 11 | 16 | 16 | 59 |
| Intertrochanteric, IM Nail and 55-75 years | 15 | 10 | 17 | 16 | 58 |
| Intertrochanteric, IM Nail and ≥ 76 years | 33 | 22 | 34 | 33 | 122 |
| Displaced femoral neck and SHS | 3 | 2 | 3 | 3 | 11 |
| Displaced femoral neck and cancellous screws | 6 | 4 | 6 | 5 | 21 |
| Undisplaced femoral neck | 3 | 2 | 3 | 3 | 11 |
Ran from Jun 2010 to primary completion in Jun 2012, 24 months.
Results were first posted in May 2019, 6 years 10 months after primary completion. A results delay was requested in Jan 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab